Cyteir Therapeutics, Inc. (NASDAQ:CYT) Q4 2021 Results Conference Call March 16, 2022 4:30 PM ET Company Participants Lisa Hayes - VP, IR and Corporate Communications Dr. Markus Renschler - President and CEO Dave Gaiero - VP, Finance Andrew Gengos - Chief Business Officer Paul Secrist - Chief Scientific Officer Conference Call Participants Anupam Rama - JP Morgan Jeff Hung - Morgan Stanley Tazeen Ahmad - Bank of America Robert Driscoll - Wedbush Securities Tim Chiang - Northland Securities Operator Good mor ...

Financial Performance - The company has incurred significant operating losses since inception, with net losses of $42.1 million for the year ended December 31, 2021, compared to $20.8 million for 2020, resulting in an accumulated deficit of $92.1 million as of December 31, 2021[378]. - The company has not generated any revenue from product sales and does not expect to do so for several years, if at all[403]. - The company anticipates significant operating losses and increased expenses related to drug development and commercialization efforts in the foreseeable future[406]. - Net cash used in operating activities for the year ended December 31, 2021, was $36.0 million, primarily due to a net loss of $42.1 million[412]. Research and Development - Research and development expenses for the year ended December 31, 2021, were $30.96 million, an increase of $14.19 million from $16.77 million in 2020, primarily due to costs related to the development of CYT-0851[399]. - The increase in research and development expenses was driven by an $8.5 million rise in costs related to RAD51-mediated HR inhibitor programs, particularly for CYT-0851[399]. - The company plans to continue increasing research and development expenses as it advances clinical trials and develops additional drug candidates[390]. - The lead program, CYT-0851, has shown preliminary single-agent activity in the phase 1/2 trial, with plans to initiate a potentially registrational trial in early 2023 for relapsed and/or refractory lymphoma and/or solid tumors[376]. Funding and Capital - The company has raised approximately $141.0 million from redeemable convertible preferred stock and $149.1 million from common stock in its initial public offering as of December 31, 2021[377]. - The company expects to finance cash needs through equity offerings, debt financings, and collaborations, with potential dilution of existing shareholders[410]. - Net cash provided by financing activities was $216.0 million for the year ended December 31, 2021, including $136.1 million from the IPO and $79.7 million from Series C Preferred Stock[415]. - The company may require additional capital for in-licenses or acquisitions of other drug candidates[406]. Cash and Liquidity - As of December 31, 2021, the company had cash and cash equivalents of $189.7 million, expected to fund operations for at least the next 12 months[382]. - As of December 31, 2021, the company had cash and cash equivalents of $189.7 million, expected to fund operations into 2024[405]. - As of December 31, 2021, the company had cash and cash equivalents of $189.7 million, up from $10.9 million in 2020[443]. - The total lease commitments for operating leases at December 31, 2021, amounted to $3.6 million, with $0.9 million due in the next twelve months[419]. Operating Expenses - General and administrative expenses rose to $11.3 million for the year ended December 31, 2021, up $7.12 million from $4.18 million in 2020, largely due to increased personnel costs and expenses associated with operating as a public company[400]. - The company expects ongoing costs associated with operating as a public company, including legal, accounting, and investor relations expenses[406]. Market and Risk Factors - The company is not currently exposed to significant market risk related to foreign currency exchange rates[445]. - An immediate 10% change in interest rates would not materially affect the fair market value of the company's investment portfolio[443]. - The company is monitoring external market conditions affecting the biotechnology industry and trends within the sector[433]. Corporate Structure and Reporting - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to delay the adoption of certain accounting standards[436]. - The company is also a "smaller reporting company," with a market value of stock held by non-affiliates below $700 million and annual revenue under $100 million[441]. - The company has opted for reduced reporting requirements, including presenting only two years of audited financial statements[437]. Stock-Based Compensation - There is significant judgment involved in stock-based compensation expense estimates, which could vary with changes in assumptions[434]. COVID-19 Impact - The company has established a cross-functional task force to address the impact of the COVID-19 pandemic on its operations and clinical trials[382].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |-------------------------------------------------------------------------|------------------------------------------------| | | | | For the transition period from | _______ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------- ...